li001

A new study suggests that the precision cell therapy Orca-T may outperform the current standard treatment, post-transplant cyclophosphamide (PTCy), for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) undergoing stem cell transplants. In this retrospective analysis, patients treated with Orca-T showed notably better outcomes than those who received PTCy. Two-year overall survival reached […]

The Centers for Medicare & Medicaid Services (CMS) has issued a permanent billing code (J9183) for Inlexzo, the first FDA-approved intravesical system delivering gemcitabine directly to the bladder. This change makes billing easier for healthcare providers and helps patients access the therapy more quickly. Inlexzo, approved in September 2025, treats patients with BCG-unresponsive non-muscle invasive

The Phase 3 TORPEdO trial compared intensity-modulated proton therapy (IMPT) with standard intensity-modulated radiation therapy (IMRT) in 205 patients with locally advanced oropharyngeal cancer. Both groups received the same radiation dose and chemotherapy. The study aimed to see if proton therapy could reduce side effects by sparing healthy tissues. IMPT showed a slight functional advantage

The Phase 3 EMERALD-3 trial has shown that a four-drug combination treatment can significantly delay disease progression in patients with unresectable hepatocellular carcinoma (HCC) who are eligible for embolization. The study tested a combination of STRIDE therapy (tremelimumab and durvalumab), lenvatinib, and TACE, compared with TACE alone. Results showed that adding these therapies led to